Brief: I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience

I'rom Co

11/07/2017 10:41

July 11 (Reuters) - I'rom Group Co Ltd  2372.T  
    
    * Says co's wholly owned unit, ID Pharma, concluded an iPS 
cell generation technology licensing agreement with UK-based 
Axol Bioscience Ltd  
    * Says unit grants non-exclusive rights of iPS cell related 
research, sales and service and sublicense rights to Axol 
Bioscience Ltd  
    * Says unit will receive upfront payments, iPS cell sales 
and service related income and royalty from Axol Bioscience Ltd  
 
    Source text in Japanese: https://goo.gl/RsB4rr 
    Further company coverage: 2372.T   
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724; 
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))